Immunitas Therapeutics has reached $97m of total funding after announcing the close of its series B round featuring more than half a dozen corporates.

Backed by one of the biggest names in pharma, the studio looks to shake up consumer healthcare markets

HiberCell has acquired genomics analytic services provider Genuity Science, which had previously been bought by WuXi AppTec before being spun off last year.

Bluesail Medical-backed mechanical heart pump developer Tongxin has collected at least $30.8m of series D funding.

National Grid Partners contributed to data protection software provider Baffle's series B round while Axa and Zendesk exited sales enablement platform developer Seismic.

Dexcel Pharma joins second funding round for BrainQ’s artificial intelligence (AI)-based technology.

Novartis Venture Fund returned as GentiBio raised money that will support the progress of its type 1 diabetes drug candidate toward clinical trials.

Blue Venture Fund led a round that included corporate venturing units GV and Optum Ventures, taking the medical imaging system developer's total funding to almost $60m.

Ventricular assistance system developer CH Biomedical closed a Baheal-backed series D round while peer-to-peer lending platform Alami secured $17.5m in a round led by EV Growth.

Early backers including Micromax Informatics are receiving 15-times returns on their investment in the health management app developer.